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Click to enter: activation of oligo-arginine cell-
penetrating peptides by bioorthogonal tetrazine
ligations†
Saskia A. Bode,‡ Suzanne B. P. E. Timmermans, ‡ Selma Eising,
Sander P. W. van Gemert, Kimberly M. Bonger * and Dennis W. P. M. Lo¨wik *
Cell-penetrating peptides are able to transport a wide variety of cargo across cell membranes. Although
promising, they are not often considered for therapeutic purposes as they lack controllable activity and
cell selectivity. We have developed an activation strategy based on a split octa-arginine cell-penetrating
peptide (CPP) that can be activated by means of bioorthogonal ligation. To this end we prepared two
non-penetrating tetra-arginine halves, functionalized either with a tetrazine or with a complementary
bicyclo[6.1.0]nonyne (BCN) group. We demonstrate that an active octa-arginine can be reconstituted in
situ upon mixing the complementary split peptides. The resulting activated peptide is taken up as
eﬃciently as the well-established cell-penetrating peptide octa-arginine. The activation of the oligo-
arginines can also be achieved using trans-cyclooctene (TCO) as a ligation partner, while norbornene
appears too kinetically slow for use in situ. We further show that this strategy can be applied successfully
to transport a large protein into living cells. Our results validate a promising ﬁrst step in achieving control
over cell penetration and to use CPPs for therapeutic approaches.
Introduction
Cell-penetrating peptides (CPPs) have the ability to penetrate
the otherwise impermeable plasma membrane. They can
transport large cargoes and as a result are potential candidates
for delivery of bioactive molecules.1–5 Although the use of CPP-
cargo constructs for cellular delivery is promising, CPPs are
hardly cell-type specic, and there is no temporal control over
their uptake.6–8 The use of CPPs for therapeutic purposes would
greatly benet if cell-type selectivity and control over their
moment of uptake could be induced.9 Various studies have been
reported on the development of activatable CPPs, using several
triggers, such as a change in pH,10 irradiation,11–13 or enzymatic
reactions.14,15 Most of these activation strategies promise to
induce cellular uptake. They generally depend on the properties
of the targeted tissue or cell type, making them sensitive for
changes in the targeted environment. Now, we think it would be
benecial to develop an activation strategy that does not need
an enzymatic activity or pH change. When we would combine it
with a targeting strategy it can rely on any receptor or other type
of marker and therefore would be more generally applicable.
Previously, we demonstrated an activation strategy for oligo-
arginines.16,17 For these peptides it is known that a minimum
amount of six arginine residues is needed to induce cellular
uptake.18,19 Making use of this characteristic, a split-CPP
approach was designed that involved truncated oligo-arginines
consisting of three to ve arginine residues and a C-terminal
cysteine. These peptides were assembled and activated
through disulde bridge formation with complementary oligo-
arginines containing an N-terminal cysteine residue. Whereas
the truncated split peptides did not induce uptake in HeLa cells,
the assembled octa- and nona-arginines were eﬃcient CPPs.
Although we demonstrated that activation of short oligo-
arginine peptides is possible by extension of their sequence,
its dependency on the formation of disulde bridges hampers
their use for in situ activation due to the dominant oxidative
environment and the presence of potentially interfering thiols in
many cellular environments. To overcome this limitation, and to
circumvent possible non-specic interactions of the split CPPs
with endogenous biomolecules, we investigated alternative
activation strategies based on the bioorthogonal tetrazine liga-
tion (Fig. 1).20
Results and discussion
Design and synthesis
The tetrazine ligation with alkenes or alkynes is based on an
inverse electron demand Diels–Alder (iEDDA) reaction and has
been used previously for several in vivo applications.21–26 For our
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in situ activation strategy of CPPs we synthesized several trun-
cated tetra-arginines equipped with a tetrazine moiety or with
a complementary alkene and alkyne reactive group. We rst
prepared a tetra-arginine, of which the C-terminus was con-
nected to a 3-aminobenzyl-6-methyl substituted tetrazine27
(R4-Tz, Fig. 2). We selected this tetrazine, because of its stability
and solubility in aqueous environments. Although the reactivity
of this tetrazine is moderate compared to other more electron-
decient less stable tetrazines, the reaction rates are still suit-
able for biological applications.28 Further, we labelled the
N-terminus with uorescein isothiocyanate (FITC), linked via
a 6-aminohexanoic acid spacer, to enable the visualization of
cellular uptake with confocal laser scanningmicroscopy (CLSM)
and quantication using ow cytometry. As an activation
partner for the R4-Tz we rst explored a tetra-arginine con-
taining the bioorthogonal bicyclo[6.1.0]nonyne (BCN-R4).25,29 In
addition, we synthesized uorescently labelled octa-arginine R8
as a reference CPP and pre-conjugated R4-b-R4 – prepared from
R4-Tz and BCN-R4 – that allowed us to determine the activity of
the fully reconstituted CPP and nd suitable conditions for
uptake (Fig. 2).
Uptake of pre-ligated conjugates
Themechanism of uptake of arginine-rich CPPs is dependent on
their concentration and their structures,30 therefore we started
by comparing the uptake of CPP R8 with that of the pre-ligated
peptide R4-b-R4 at 5 mM, 10 mM, 15 mM and 20 mM using
confocal uorescence microscopy (Fig. 3). As a control, we
measured the uptake of the truncated peptide R4-Tz. At low
concentrations (5 mM and 10 mM), we did not observe any uptake
of the truncated peptide R4-Tz, which was in accordance with
earlier ndings that demonstrated that at least six arginines
within one sequence are required for eﬃcient cellular uptake.16
At higher concentrations (15 mM and 20 mM) we observed some
Fig. 1 Overview of the click to enter strategy.
Fig. 2 Structures of oligo-arginine peptides used in this study.
Fig. 3 CLSM micrographs corresponding to cellular uptake studies in
HeLa cells. The concentration of the CPP increases from top to
bottom (5, 10, 15 and 20 mM). The experiments were performed with
reference peptide R8, pre-ligated R4-b-R4 and truncated R4-Tz at
37 C, with an incubation time of 30 minutes in serum-containing
medium.
702 | Chem. Sci., 2019, 10, 701–705 This journal is © The Royal Society of Chemistry 2019
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minor cellular internalization. The pre-ligated peptide R4-b-R4
and R8 were taken up at all concentrations, however, the
mechanism of uptake varied considerably between the peptide
concentrations (Fig. 3). At low concentrations, R8 and R4-b-R4
were taken up most likely via endocytosis, suggested by the
punctuate uorescence in the cells, while strong cytosolic uptake
was observed at the higher concentrations, possibly via nucle-
ation zones as has been reported before by us16 and for arginine
rich CPPs in general.31 The concentration dependent uptake of
arginine-rich CPPs has been described in the literature before,
however, it was surprising that the concentration at which HeLa
cells switched to a diﬀerent uptakemechanism diﬀered between
the two similar peptides R8 and R4-b-R4. From these results and
for uniformity, we concluded that 5 mM would be the best
concentration to compare in situ activation for these small
molecules.
In situ activation
The eﬃcient cellular uptake of the R4-b-R4 peptide, prompted
us to study the in situ activation of oligo-arginines using
the bioorthogonal tetrazine ligation. We commenced by
co-incubating HeLa cells with 5 mM R4-Tz in serum-containing
culture medium and added 5 eq. of BCN-R4 to allow ligation
and formation of R4-b-R4. We included R8 as positive control,
while R4-Tz served as negative control. As seen by CLSM, the
uptake of in situ activated R4-Tz + BCN-R4 at 30 minutes was
similar to the uptake of R8 as well as R4-b-R4, indicating that in
situ activation of R4-Tz to R4-b-R4 is possible at these condi-
tions (Fig. 4 and S1†).
Next, we evaluated whether uptake could be improved by
increasing the amount of activating agent BCN-R4 or by pro-
longing the incubation time. We found that addition of 10 eq. of
BCN-R4 instead of 5 eq. did not improve uptake (Fig S2†), while
reducing the amount of BCN-R4 from 5 eq. to 2.5 eq. resulted in
a signicant decrease in cellular uptake (Fig. S3†). Subse-
quently, we assessed the eﬀect of incubation time on in situ
activation of R4-Tz. Using similar conditions as above we
observed CPP uptake already aer 30 minutes and that uptake
increased slightly over time. At 60minutes, similar uptake levels
were reached as observed aer 90 minutes (Fig. S3†). From
these results we concluded that 30–60 minutes of incubation
using 5 eq. of BCN-R4 activating agent are needed for suﬃcient
CPP uptake.
To study the eﬀect of the tetrazine ligation rate, we addition-
ally prepared tetra-arginine fragments that were N-terminally
equipped with either a norbornene (Norb-R4), or a trans-cyclo-
octene (TCO-R4) moiety (Fig. 2). Norbornene and TCO are known
to display a respectively lower and higher reactivity towards tet-
razines compared to BCN.25We compared the uptake of the in situ
activation of R4-Tz by the tetra-arginines with the diﬀerent bio-
orthogonal reagents using CLMS (Fig. 4A). To acquire the uptake
eﬃciency more quantitatively, we additionally measured the
cellular uorescence of the various tetrazine reactions with ow
cytometry (Fig. 4B). HeLa cells were incubated with R8 at 5 mM for
30 minutes at 37 C in serum containing medium and compared
to cells that were incubated for 30 minutes with 5 mM R4-Tz to
which 5 equivalents of BCN-R4, Norb-R4, or TCO-R4 were added
respectively. As shown in Fig. 4, truncated splitR4-Tz again hardly
gave any uptake. Interestingly, the R4-Tz peptide incubated with
Norb-R4 showed only poor uptake while both activation with
BCN-R4 and TCO-R4 gave uptake that was comparable to refer-
ence peptide R8. Interestingly, no signicant diﬀerence was
found between BCN and TCO.
Protein cargo
As our activation strategy is feasible using an iEDDA conjugation
reaction for a small molecule uorophore we next explored
whether our strategy could also be used for the induced uptake of
a much larger protein cargo. To this end we selected uorescently
labelled human serum albumin (HSA) as amodel protein. This 66
kDa protein contains a single free cysteine that allowed us to site
selectively modify the protein with a tetrazine. This was achieved
by rst reacting the cysteine of HSA with a bi-functional mal-
eimide-DBCO32 linker and reaction of free lysines of HSA with
Fig. 4 HeLa cell uptake studies to test in situ activation. (A) CLSM
micrographs for HeLa cell uptake studies to test in situ activation.
CSLM images are depicted for positive control R8, negative control
R4-Tz and in situ activated R4-Tz + BCN-R4/Norb-R4/TCO-R4. For
the in situ activation HeLa cells were incubated with 5 mM R4-Tz and 5
eq. of BCN-R4/Norb-R4/TCO-R4 for 30 minutes. (B) Flow cytometry
results at 5 mM in serum-containing medium for 30 minutes of
incubation.
This journal is © The Royal Society of Chemistry 2019 Chem. Sci., 2019, 10, 701–705 | 703
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FITC providing uorescent HSA-DBCO. A tetra-arginine with an
N-terminal azide and a C-terminal tetrazine, N3-R4-Tz, was
conjugated in a sequential step yielding HSA-R4-Tz (Fig. 5A).
In addition, we prepared an octa-arginine protein conjugate
(HSA-R8) using N3-R8, for comparison.
Using HSA as cargo conjugated to a tetrazine oligo-arginine,
activation with the BCN-R4 peptide under the conditions
employed above, we did not observe signicant cellular uptake
as evidenced by FACS as well as confocal microscopy. Fortu-
nately, incubation at a slightly higher concentration (10 mM)
and increased time (90 min) resulted in clear uptake of theHSA-
R4-Tz protein which was in situ activated by conjugation to BCN-
R4 (Fig. 5B). Similar uptake levels were observed for HSA-R8
while unreacted HSA-R4-Tz was only poorly taken up. These
qualitative results were quantied using ow cytometry using
the same conditions (Fig. 5C) and substantiate that our in situ
CPP activation strategy is suitable for the delivery of a large
protein cargo.
Conclusions
In conclusion, we have successfully developed an in situ acti-
vation strategy for oligo-arginine CPPs based on a bio-
orthogonal tetrazine ligation between two split tetra-arginine
parts. The norbornene-based reaction did not show kinetics
suitable for in situ application, but both BCN and TCO were
eﬃcient in reconstituting active CPPs. This provides a valuable
method for probe design and is the basis for further eﬀorts in
this line of research. Moreover, using BCN eﬃcient cellular
uptake was observed for a low molecular weight uorescent
probe as well as a large protein cargo. Future eﬀorts in this line
of research are to incorporate homing peptides or targeting
ligands33 in our tetra-arginine activation strategy, providing the
rst steps towards a targeted and site-selective cargo delivery
strategy involving activatable CPPs.
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